Bioavailability Clinical Trial
Official title:
A Double-blind, Randomized, Three-period, Three-way Crossover Design, Placebo Controlled Single Dose Study to Assess the Bioavailability of Sodium Oligo-mannurarate (GV-971) Capsule 150 mg, 300mg, 450mg in Healthy Chinese Male Subjects
Verified date | December 2017 |
Source | Shanghai Greenvalley Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the Bioavailability for GV-971 capsules of 150 mg, 300mg, and 450mg after administration of single oral doses of 900mg in healthy Male subjects.
Status | Completed |
Enrollment | 15 |
Est. completion date | November 2017 |
Est. primary completion date | February 24, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male subjects; 2. Age:=18 and =45 on the date signing informed consent 3. Body mass index (BMI): 18-25 kg/m2 and the weight =50 kg; 4. Subjects are able to understand the study procedures and methods, and willing to strictly comply with the protocol and give written informed consent. Exclusion Criteria: A subject will be excluded if the answer to any of the following criteria is "yes":: 1. Clinically significant abnormalities in physical examination and laboratory test results or 12-lead ECG, etc. in screening; 2. Clinically significant abnormalities in Chest X-ray or abdominal B-ultrasound examination 3. Positive serology screen for Hepatitis B( HBsAg), Hepatitis C(HCV), HIV and USR unheated serum reagin test. 4. Smoking more than 10 cigarettes a day, drugs or alcohol abuse within 6 months prior to screening 5. Participation in any investigational drug or medical instrument study within 3months prior to screening, participation in 3 and more than 3 drug tests in a recent year; 6. Serious infection, trauma and major surgery within 4weeks prior to screening; 7. Blood donation of =400 mL or severe blood lose and the volume of blood loss =400 mL within 4 weeks prior to screening, receiving blood transfusion treatment within 8 weeks prior to screening ; 8. Use of any prescription medicine or herbal remedy, over the counter medication or dietary supplements such as vitamin, calcium within 2 weeks prior to screening. 9. Use of heparin, alginic sodium diester , mannose ester within 4 weeks prior to screening; 10. Vegetarian or person with dietary restrictions 11. Subjects able to father a child are unwilling to use highly effective physical form of birth control from the trial period until 3 months after the completion of study. 12. With diseases which could impact on the absorption, distribution, metabolism and excretion (ADME) of study drugs or protocol adherence in the opinion of the investigator (such medical disorder/disease may relate to ccardiovascular, liver, kidney, digestive, immune, blood, endocrine, metabolic, cancer, neuropsychiatric,etc ); 13. Subjects may be allergic to GV-971 in the opinion of the investigator. 14. Any other reasons that the subject is not eligible for participation in the study in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Phase-I Clinical Research Unit at Shanghai Xuhui Center hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Greenvalley Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax - maximum observed concentration, is obtained directly from the plasma concentration curve | 3 days | ||
Primary | AUC0-last-the area under the concentration-time curve from zero to the time of the last measurable concentration; computed using the linear trapezoidal rule | 3 days | ||
Primary | AUC0-8-the area under the concentration-time curve from zero to the infinity, computed as AUC0-8=AUC0-last+Clast/?z (?z is the terminal phase rate constant) | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06043739 -
Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02557139 -
Bioavailability of Belumosudil (KD025) in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT02010944 -
A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
|
Phase 1 | |
Not yet recruiting |
NCT01136551 -
Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
|
N/A | |
Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
Completed |
NCT04097808 -
Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects
|
N/A | |
Active, not recruiting |
NCT06098001 -
Bioavailability Study of Hemp Phenolics
|
N/A | |
Completed |
NCT01912144 -
Absorption of Phenolic Acids From Coffee in Humans
|
N/A | |
Completed |
NCT03915626 -
Effect of Heat on Rivastigmine TDS Products
|
Early Phase 1 | |
Completed |
NCT01448772 -
Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT01464450 -
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT01181973 -
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00858767 -
Arabic Gum-Absorption Study
|
N/A | |
Completed |
NCT04113564 -
Absolute Oral Bioavailability of Remimazolam
|
Phase 1 | |
Completed |
NCT04645394 -
Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study
|
N/A | |
Completed |
NCT03485885 -
Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
|
||
Completed |
NCT05840848 -
Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males
|
N/A | |
Completed |
NCT01789359 -
Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding
|
N/A | |
Completed |
NCT01638143 -
Bio-equivalence Study
|
N/A | |
Completed |
NCT00755872 -
Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
|
Phase 1 |